Literature DB >> 29856557

Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective.

Jeffrey A Lieberman1.   

Abstract

Entities:  

Year:  2018        PMID： 29856557      PMCID： PMC5980457          DOI： 10.1002/wps.20543

Source DB:  PubMed          Journal:  World Psychiatry        ISSN： 1723-8617            Impact factor:   49.548


× No keyword cloud information.
  7 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

Review 2.  Duration of untreated psychosis as predictor of long-term outcome in schizophrenia: systematic review and meta-analysis.

Authors:  Matti Penttilä; Erika Jääskeläinen; Noora Hirvonen; Matti Isohanni; Jouko Miettunen
Journal:  Br J Psychiatry       Date:  2014-08-01       Impact factor: 9.319

3.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

Review 4.  Neuroleptics and the natural course of schizophrenia.

Authors:  R J Wyatt
Journal:  Schizophr Bull       Date:  1991       Impact factor: 9.306

5.  Changes in cortical thickness during the course of illness in schizophrenia.

Authors:  Neeltje E M van Haren; Hugo G Schnack; Wiepke Cahn; Martijn P van den Heuvel; Claude Lepage; Louis Collins; Alan C Evans; Hilleke E Hulshoff Pol; René S Kahn
Journal:  Arch Gen Psychiatry       Date:  2011-09

6.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

Review 7.  The natural course of schizophrenia and effective maintenance drug treatment.

Authors:  J M Davis; S Andriukaitis
Journal:  J Clin Psychopharmacol       Date:  1986-02       Impact factor: 3.153
  7 in total
  3 in total

Review 1.  Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.

Authors:  William S Stone; Michael R Phillips; Lawrence H Yang; Lawrence S Kegeles; Ezra S Susser; Jeffrey A Lieberman
Journal:  Schizophr Res       Date:  2022-03-25       Impact factor: 4.662

2.  Application value of UPLC-MS/MS in detecting serum concentration of anti-schizophrenic drugs in patients with mental illnes.

Authors:  Shaochang Wu; Guidong Zhu; Dajin Zhou; Hongtao Xu; Longyou Zhao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function.

Authors:  Lujie Yang; Xia Qi
Journal:  Pak J Med Sci       Date:  2021 May-Jun       Impact factor: 1.088
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.